• Explore /
  • Poster
  • / A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report.

A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report.

Abstract Poster

Authors

null

Brian Gastman

Cleveland Clinic Lerner College of Medicine, Cleveland, OH

Brian Gastman , Steven Fling , George Ansstas , Pauline Funchain , Ann W. Silk , Philip Adam Friedlander , Brendan D. Curti , Yan Xing , Oanh Nguyen , Ann Christensen , Sara Ferrando-Martinez , Andreanne Lacroix , Byung Ha Lee , David M. Miller , Jeffrey A. Sosman , Jean Fan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03901573

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9561)

DOI

10.1200/JCO.2022.40.16_suppl.9561

Abstract #

9561

Poster Bd #

154

Abstract Disclosures

Similar Posters

First Author: Thomas Lillie

First Author: Chunmei Bai

Poster

2023 ASCO Gastrointestinal Cancers Symposium

A phase Ib/II study of atezolizumab plus tivozanib in pancreatic, gallbladder, and bile duct malignancies.

A phase Ib/II study of atezolizumab plus tivozanib in pancreatic, gallbladder, and bile duct malignancies.

First Author: Brian Hemendra Ramnaraign

First Author: Xiao-Li Wei